Separately, Maxim Group reiterated a hold rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th.
DelMar Pharmaceuticals (NASDAQ DMPI) opened at $1.31 on Thursday. DelMar Pharmaceuticals has a 1 year low of $0.78 and a 1 year high of $5.39. The company has a market capitalization of $28.30, a PE ratio of -1.93 and a beta of 1,227.20.
In related news, CEO Saiid Zarrabian acquired 60,900 shares of the stock in a transaction on Tuesday, November 14th. The stock was acquired at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Several institutional investors have recently bought and sold shares of DMPI. Susquehanna International Group LLP bought a new stake in shares of DelMar Pharmaceuticals in the 3rd quarter worth $306,000. Sabby Management LLC bought a new stake in shares of DelMar Pharmaceuticals in the 2nd quarter worth $1,484,000. Finally, Franklin Resources Inc. bought a new stake in shares of DelMar Pharmaceuticals in the 2nd quarter worth $2,477,000. 16.91% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Reiterates $12.00 Price Target for DelMar Pharmaceuticals (DMPI)” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://stocknewstimes.com/2018/01/19/delmar-pharmaceuticals-dmpi-pt-set-at-12-00-by-hc-wainwright.html.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.